Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1864 results
April 2019
-
Story Discovery
Bringing gene therapy into focus
Dr. Botond Roska says we should keep our eyes on gene therapy.
-
Press Release
Novartis updates on the migraine collaboration with Amgen
Basel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of… -
In The News
Medicines and transformative effect
In this Bloomberg interview, Vas Narasimhan, CEO of Novartis shares his thoughts on how medicines can have a transformative effect. -
Press Release
Sandoz resubmits biosimilar pegfilgrastim application to US FDA
Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one… -
Featured News
Sustaining the momentum toward universal health coverage in Africa
The first pan-African Novartis Social Business stakeholder dialogue took place in Kampala, Uganda, on March 20, 2019.
-
Press Release
Novartis first-in-class Cosentyx® approved in China for psoriasis patients
China Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is… -
Press Release
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy … -
Press Release
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre
Acquisition will give Novartis one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system Selective inhibition of the NLRP3…
March 2019
-
Key Release
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients… -
Story From Our Labs
What goes wrong with the window to the soul in glaucoma?
Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.
-
Key Release
Novartis plans for Alcon spin-off on April 9, 2019
Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange… -
Story Discovery
Experimental gene therapy discovered in-house enters clinical testing
Novartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.